ReShape Lifesciences Inc. (NASDAQ:RSLS) Sees Large Growth in Short Interest
by Tristan Rich · The Markets DailyReShape Lifesciences Inc. (NASDAQ:RSLS – Get Free Report) was the target of a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 81,700 shares, a growth of 226.8% from the October 31st total of 25,000 shares. Approximately 12.4% of the shares of the stock are sold short. Based on an average daily volume of 225,000 shares, the days-to-cover ratio is presently 0.4 days.
ReShape Lifesciences Price Performance
RSLS stock traded down $0.09 during mid-day trading on Wednesday, hitting $5.59. The stock had a trading volume of 18,549 shares, compared to its average volume of 99,127. The firm has a fifty day simple moving average of $5.71 and a 200 day simple moving average of $9.26. ReShape Lifesciences has a 52 week low of $4.60 and a 52 week high of $34.22.
ReShape Lifesciences Company Profile
ReShape Lifesciences Inc provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; Lap-Band 2.0 System, an adjustable postoperatively to increase or decrease the pressure to the band in order to optimize an individual's comfort and therapy effectiveness; and ReShape Calibration Tubes, that fits the lesser curvature of the stomach to reach the pylorus.
Further Reading
- Five stocks we like better than ReShape Lifesciences
- Ride Out The Recession With These Dividend Kings
- Microsoft Stock Gets a $550 Price Target: Time to Get Excited
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Trump Tariffs in Focus: 2 Chinese Stocks to Own and 2 to Avoid
- What Are Dividend Champions? How to Invest in the Champions
- 2 Generic Drug Stocks Ready to Surge in 2025